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The Journal of Molecular Diagnostics has developed a formal 
Scientific Integrity Policy in an effort to define more clearly issues of 
scientific misconduct in journal publishing. This document defines 
the common issues relating to appropriate scientific conduct as well 
as the procedures that will be followed should misconduct issues 
arise. In addition the Instructions to Authors (http://www.journals.
elsevierhealth.com/periodicals/jmdi/authorinfo) and Instructions to 
Reviewers (http://www.journals.elsevierhealth.com/periodicals/jmdi/
content/reviewers) have been updated to reflect these changes.  
The policy is based on recommendations from the Uniform 
Requirements for Manuscripts Submitted to Biomedical Journals 
(http://www.icmje.org), the CSE White Paper on Promoting Integrity 
in Scientific Journal Publications (http://www.councilscienceeditors.
org/editorial_policies/white_paper.cfm), and the US Department of 
Health and Human Services’ Office of Research Integrity 
(http://ori.dhhs.gov/). It should be noted that willful misconduct does 
not include incidents of honest misjudgment or inadvertent error. 
Any questions regarding the official policy of the Journal should be 
directed to the Editorial Office at 301-634-7959 or jmd@asip.org. 
Author Conduct 
General Authorship Guidelines. Uniform Requirements for 
Manuscripts Submitted to Biomedical Journals (http://www.icmje.org)
defines authorship as “1) substantial contributions to conception and 
design, or acquisition of data, or analysis and interpretation of data; 
2) drafting the manuscript or revising it critically for important 
intellectual content; and 3) final approval of the version to be 
published. Authors should meet conditions 1, 2, and 3.” When work 
has been performed by a large, multi-center group, the group should 
designate individuals who accept direct responsibility for the 
manuscript on behalf of the group. These individuals should fully 
meet the criteria above and should disclose conflicts of interest (see 
below) on behalf of the group. All members of the group who meet 
authorship criteria should be provided for listing as a footnote.  
When submitting a manuscript to the Journal, the corresponding 
author takes responsibility on behalf of all authors for the authorship, 
authenticity and integrity of the research being reported. The email 
contact information of ALL authors is required so the Journal may 
formally contact the authors regarding any aspect of manuscript 
submission. If an author is removed during the course of revision of 
the manuscript, written explanation and consent by the removed 
author (signed letter or personal email) should be provided. Any 
change made to the list of authors (addition, removal, change in 
order) after manuscript acceptance requires consent of all authors and 
editorial approval. Authorship disputes are to be resolved by the 
authors and/or their institutions, not by the Journal. 
Because inclusion in the Acknowledgments may give the appearance 
of endorsement of the manuscript and its findings, authors should 
obtain permission from all individuals named in the 
Acknowledgments who contributed substantially to the work reported 
(eg, data collection, analysis, or writing/editing assistance) but did 
not fulfill the authorship criteria. Likewise, authors should receive 
permission from all individuals named as sources for personal 
communication or unpublished data. Such permissions should be 
affirmed by the corresponding author in the cover letter.  
Ghostwriting. As stated above, all persons contributing to the paper 
but not meeting authorship criteria should be listed in the 
Acknowledgments section. Further, any funding for writing support 
should be fully disclosed. If an outside source funded the assistance, 
the authors of the paper should also affirm that they are solely, and 
independently, responsible for the interpretation of the data and that 
they had full and open access to all of the data. It is considered 
unethical for any entity (eg, governmental, private, or commercial) 
with direct financial or personal interests to restrict the use of data or 
their interpretation for the sole purpose of presenting data in a 
manner that is favorable to its own interests or those of its affiliates. 
It is also unethical for any entity to be responsible for data gathering, 
interpretation, and/or presentation and then to solicit outside 
"authors" for the paper, as a means of hiding its relationship with the 
data.
Peer Review Process. The Journal takes great care to secure the 
confidentiality and integrity of the peer-review process. It is the 
practice of the Journal to conduct a blinded peer-review process. 
Thus, it is considered a violation of this process for authors to 
identify or attempt to communicate directly with peer reviewers or 
Associate Editors regarding their manuscript. All editorial 
communications should be directed through the Editorial Office at 
jmd@asip.org. The Editors will consider any deliberate ethical 
violation in either the reported research or the manuscript preparation 
and review to be actionable misconduct, the potential results of which 
may be manuscript rejection or public article retraction, reporting of 
conduct to the authors’ governing institutions, and/or the denial to 
consider any future submissions to the Journal.  
Authors may request that specific reviewers not be used due to prior 
collaborations, known conflicts of interest, or direct competition. The 
Editors will make every effort to respect requests that are well-
founded; however, the Editors do have the authority to utilize such a 
reviewer if it is necessary for expert peer review.   
To aid the review process, authors should be ready to comply with 
Editors’ requests for copies of any similar works in preparation, 
copies of cited manuscripts that are submitted or in press, and/or 
supporting manuscript data (eg, data not shown but summarized in 
the manuscript). Failure to do so may result in rejection of the 
manuscript without further review.  
Financial Disclosure and Conflicts of Interest. All authors must 
disclose any current or former relationships (eg, employment, 
consultancies, board membership, stock ownership, funding, 
honoraria, expert testimony, patents or royalties, travel 
reimbursements, industry-supplied free reagents, etc.) with any 
organization or entity having a direct financial or personal interest in 
the subject matter or materials discussed in the manuscript. Authors 
should err on the side of full disclosure and should contact the 
Editorial Office if they have questions or concerns. This information 
should be provided at the time of submission (for new and revised 
manuscripts). All authors will be required to complete an online 
disclosure form following acceptance; details are provided in the 
acceptance letter. Failure to disclose conflicts of interest may result in 
manuscript rejection or editorial retraction of the article. 
Ethical Treatment of Research Subjects. If human subjects or 
samples were used, authors must affirm that the research protocol 
was approved by the appropriate institutional review boards or ethics 
committees for human (including use of human cells or tissues) 
experiments and that all human subjects provided appropriate 
informed consent. To protect patient privacy, identifying information 
such as names, initials, or hospital numbers should not be published 
unless the information is essential for scientific purposes and the 
patient (or parent or guardian) gives written informed consent for 
publication. If race/ethnicity is reported, authors should state who 
determined race/ethnicity, how the options were defined, and why 
race/ethnicity was important in the study. Authors should be prepared 
to provide study protocol number(s) if requested. 
Ethical Treatment of Animals. If animal experiments were 
performed, authors must affirm that the research protocol was 
approved by the appropriate institutional review boards or ethics 
committees for animal experiments and that regulations concerning 
the use of animals in research were adhered to. Authors should be 
prepared to provide study protocol number(s) if requested. 
Copyright. Copyright of published manuscripts is held by the 
Association for Molecular Pathology and the American Society for 
Investigative Pathology, which must receive the assignment of 
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copyright from the authors of accepted manuscripts. For US 
government employees, the above assignment applies only to the 
extent allowable by law. See http://www.asip.org/pubs/jmdrights.pdf 
for details. Requests to republish copyrighted materials, including the 
planned use, should be directed to the Editorial Office at 301-634-
7959 or jmd@asip.org. 
Publishing in The Journal of Molecular Diagnostics automatically 
places authors in compliance with NIH Public Access Policy (see 
http://publicaccess.nih.gov/ submit_process.htm, Submission Method 
A). Any article noted as being funded by NIH, HHMI, Wellcome 
Trust, or MRC is deposited in PubMed Central (PMC), to be made 
available to the public twelve months after final print publication 
(unless the funding agency stipulates a sooner release date, such as 
six months). Authors therefore should NOT complete a separate 
deposit of their material but will be contacted by PubMed Central for 
grant verification once the article has been received by the PMC 
article system. For information on how to cite articles in NIH grant 
applications, please visit http://www.asip.org/pubs/AuthorNotice.cfm.
Contact healthpermissions@elsevier.com regarding permission to 
deposit manuscripts in other government-sponsored repositories in 
cases where The Journal of Molecular Diagnostics does not have a 
system in place to automatically deposit materials on behalf of their 
authors. Deposit of accepted or published manuscripts in any non-
JMD repository without prior permission by the Journal is a violation 
of copyright. 
Embargo Policy. All information regarding the content of submitted 
or accepted manuscripts is strictly confidential. Information 
contained in or about accepted articles cannot appear in print, audio, 
video, or digital form or be released by the news media until the 
Journal embargo date has passed, not to exceed the publication date 
of the article. For detailed information on embargo release dates or 
for news media requests for preprint copies of specific articles, 
contact asipproduction@elsevier.com. 
Scientific Misconduct. According to the US Office of Research 
Integrity (http://ori.dhhs.gov/), “fabrication is making up data or 
results and recording or reporting them; falsification is manipulating 
research materials, equipment, or processes, or changing or omitting 
data or results such that the research is not accurately represented in 
the research record; plagiarism is the appropriation of another 
person’s ideas, processes, results, or words without giving 
appropriate credit.” The Journal has a zero tolerance policy for such 
matters. For details regarding how the Journal handles such matters, 
see the later section on Allegations of Misconduct.  
Fabrication of Data. Any evidence of fraudulent methods, data, or 
data analysis may prompt the Editors to request an explanation and 
access to original data, which the authors must supply.  
Falsification of Data. The results presented in the manuscript must 
accurately represent the data obtained in the course of authors’ 
studies; omission of contradictory or negative data in an effort to 
support the main hypothesis is unacceptable. Taking photographs of 
the same source under varied fields of view, light intensity, 
magnifications, or contrast conditions without disclosing that the data 
are not unique to the present study constitutes suspect scientific 
conduct. Further, unless serial sections are used, the publication of 
identical-appearing images labeled with different staining techniques 
in different papers raises legitimate questions. No specific feature 
within an image may be enhanced, obscured, moved, removed, or 
introduced. The grouping of images from different parts of the same 
gel or blot, or from different gels or blots, fields, or exposures must 
be made explicit by the arrangement of the figure (eg, using dividing 
lines) and in the figure legend. Adjustments of brightness, contrast, or 
color balance are acceptable only if they are applied to the whole 
image, whether experimental or control image, and as long as they do 
not obscure or eliminate any information present in the original 
(Portions adapted with permission from the JCB). Any evidence of 
inappropriate manipulation may prompt the Editors to request an 
explanation and access to original data, which the authors must make 
available.  
Plagiarism. Authors should carefully note that the use of another 
person’s data or ideas without permission constitutes plagiarism. 
Authors may not republish copyrighted Journal material in whole or 
in part without the express permission of the copyright holder, the 
American Society for Investigative Pathology and the Association for 
Molecular Pathology. Likewise, copyrighted material previously 
published in another form may not be published in the Journal 
without express permission from the original copyright holder. These 
rules cover work previously written by the authors. Authors wishing 
to republish images, tables, or text should provide proof of such 
permission with their submission and should include the appropriate 
attribution in the figure or table legend or in the text.  
Redundant Publication. “Redundant (or duplicate) publication is 
publication of a paper that overlaps substantially with one already 
published in print or electronic media,” as defined by the Uniform 
Requirements for Manuscripts Submitted to Biomedical Journals 
(http://www.icmje.org). Authors must certify upon submission that 
the manuscript has not been accepted or published elsewhere and that 
it is not currently under review at another journal. Likewise, 
manuscripts under consideration by the Journal should not be 
submitted or published elsewhere. Publication of short abstracts in 
meeting proceedings does not violate this standard. Submissions will 
be ineligible for review if previously published in any form (print or 
online) other than as an abstract. This includes any public posting of 
raw manuscripts or pre-reviewed material. If there is any doubt, the 
authors should contact the Editorial Office for guidance. 
Reviewer Conduct 
Peer Review Process. Reviewers are expected to take their obligation 
seriously and to consider carefully the merits of the manuscript being 
assessed. Any delays in completing a review should be brought to the 
immediate attention of the Editorial Office so that we may assess the 
situation and make adjustments as needed. It is the practice of The 
Journal of Molecular Diagnostics to conduct a blinded peer-review 
process; it is considered a violation of this process for peer reviewers 
to identify themselves or attempt to communicate directly with 
authors regarding the reviewed manuscript without the express 
permission of the Editors. All editorial communications should be 
directed through the Editorial Office at jmd@asip.org. The Editors 
will consider any deliberate ethical violation during peer review of a 
manuscript to be actionable misconduct, the potential results of 
which may be reporting of conduct to the Reviewer’s governing 
institution, dismissal as a peer reviewer for the Journal, and/or the 
denial to consider any future submissions to the Journal.  
Confidentiality. The manuscript is considered a privileged 
communication. When reviewing a manuscript for the Journal, the 
peer reviewer takes responsibility for maintaining its confidentiality. 
Reviewers should not retain copies of submitted manuscripts for 
personal use after completing their review. Reviewers are not 
allowed to make any use of the work described in the manuscript or 
take advantage of the knowledge gained by reviewing it until and 
unless it is published.  
If necessary, the manuscript may be discussed with a colleague in an 
effort to reach a decision. In such instances, the Reviewer must 
inform the colleague of the manuscript’s confidentiality and ask that 
they disclose any potential conflicts of interest. Information regarding 
additional assistance (colleague’s name and disclosure information as 
well as a description of the level of assistance) should be included in 
the “Confidential Comments to the Editor” portion of the online 
reviewer form. 
Financial Disclosure and Conflicts of Interest. Reviewers must 
disclose to the Editors any current or former relationships (eg, 
employment, consultancies, board membership, stock ownership, 
funding, honoraria, expert testimony, patents or royalties, travel 
reimbursements, etc.) with any organization or entity having a direct 
financial or personal interest in the subject matter or materials 
discussed in the manuscript that could bias their opinions of the 
manuscript. Reviewers should also consider potential conflicts of 
interest arising from personal relationships or academic competition. 
Personal relationships include family members, colleagues (such as 
collaborators, mentors, students, or trainees), or associates at a 
Reviewer’s institution. At least three years should elapse between the 
ending of such a relationship and participation in any review. 
However, for certain relationships such as student-mentor, three 
years may not be sufficient time, especially if both investigators 
continue to work in the same field. Thus, Reviewers must err on the 
side of caution and decline any assignments in which the suggestion 
of a conflict or bias could be raised. By agreeing to review a 
manuscript, Reviewers implicitly affirm that any potential conflicts 
of interest have been disclosed to the Editors and that they are able to 
provide an impartial review of the manuscript. 
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Editor Conduct 
Peer Review Process. The Editor-in-Chief, Senior Associate Editor, 
and Associate Editors, are expected to take their obligation seriously 
and to maintain the highest standard of ethics during the peer-review 
process. Editors should perform their editorial duties without bias for 
or against any person or institution. Any delays in completing the 
disposition of a manuscript should be brought to the immediate 
attention of the Editorial Office so that the situation may be resolved. 
It is considered a violation for Editors to communicate directly with 
authors regarding their manuscript outside of normal editorial 
practices. It is also a violation for the Editors to reveal Reviewers’ 
names to authors without Reviewer consent; as the Journal conducts 
a blinded peer-review process, such revelations are extremely rare. 
Any deliberate ethical violation during peer review of a manuscript is 
considered to be actionable misconduct, the potential results of which 
may be reporting of conduct to the Editor’s governing institution, 
dismissal as an Editor for the Journal, and/or the denial to consider 
any future submissions to the Journal.  
Editors should respect author requests to exclude specific reviewers 
due to prior collaborations, known conflicts of interest, or direct 
competition when such requests are well-founded; however, Editors 
have the authority to utilize such a reviewer if they feel it is necessary 
for expert peer review. Such decisions should be made only after 
careful consideration and after other options have been exhausted 
Confidentiality. The Editors are subject to the same confidentiality 
requirements as Reviewers. Further, Editors must not disclose 
information about manuscripts (including their receipt, content, status 
in the reviewing process, Reviewers’ comments, or final disposition) 
to anyone other than the authors, Reviewers, and Journal staff. 
Editors should not retain copies of submitted manuscripts for 
personal use after completing their disposition. Editors are not 
allowed to make any use of the work described in the manuscript or 
take advantage of the knowledge gained by reviewing it until and 
unless it is published.  
Financial Disclosure and Conflicts of Interest. Editors must also 
carefully consider whether there exist any current or former 
relationships (eg, employment, consultancies, board membership, 
stock ownership, funding, honoraria, expert testimony, patents or 
royalties, travel reimbursements, etc.) with any organization or entity 
having a direct financial or personal interest in the subject matter or 
materials discussed in the manuscript that could bias their opinions of 
the manuscript. Editors should also consider potential conflicts of 
interest arising from personal relationships or academic competition. 
Personal relationships include family members, colleagues (such as 
collaborators, mentors, students, or trainees), or associates at the 
Editor’s institution. At least three years should elapse between the 
ending of such a relationship and participation in any review. 
However, for certain relationships such as student-mentor, three 
years may not be sufficient time, especially if both investigators 
continue to work in the same field. Thus, Editors must err on the side 
of caution and decline any assignments in which the suggestion of a 
conflict or bias could be raised. By agreeing to review a manuscript, 
the Editor implicitly affirms that conflicts do not exist. In cases 
where the Editor-in-Chief has a conflict of interest, the Senior 
Associate Editor or another Associate Editor will handle the full 
disposition of the manuscript.   
Staff Conduct 
Peer Review Process. When handling a manuscript for the Journal, 
the Journal staff is expected to interact courteously and respectfully 
with authors, Reviewers, and Editors. They should not misrepresent 
the review process to authors or Reviewers. They should not forge, 
fabricate, or alter the scientific content of Reviewer comments. They 
should ensure timely disposition of reviewed manuscripts and 
publication of accepted manuscripts.  
Confidentiality. The Journal staff is subject to the same 
confidentiality standards as Editors. It is considered a violation of this 
confidentiality for staff to reveal Reviewer names or to communicate 
directly with authors regarding their manuscript outside of normal 
editorial practices.  
Allegations of Misconduct 
Reporting Suspected Misconduct. To maintain the integrity and high 
standards of the scientific publishing process, the Journal welcomes 
reporting of possible misconduct or other concerns related to 
manuscripts published or under review by the Journal. Suspected 
misconduct relating to authors, Reviewers, or Editors should be 
reported in writing to the Editorial Office at The Journal of
Molecular Diagnostics, 9650 Rockville Pike, Bethesda, Maryland, 
USA 20814-3993 or jmd@asip.org. Issues relating to staff conduct 
should be directed to the ASIP Executive Officer (AMP Executive 
Officer Emeritus) at American Society for Investigative Pathology, 
9650 Rockville Pike, Bethesda, Maryland, USA 20814-3993 or 
mesobel@asip.org. Willful misconduct does not include incidents of 
honest misjudgment or inadvertent error. 
The anonymity of the whistleblower(s) will be maintained throughout 
these procedures. With respect to all other communications arising 
from examination of misconduct, the ability to effectively investigate 
and administer an allegation of scientific misconduct shall be 
carefully balanced with the need to maintain confidentiality in order 
to protect the rights and reputations of all concerned. 
Procedures for Suspected Author Misconduct. Upon written 
notification of possible author misconduct, the Editors and Editorial 
Office will first perform a preliminary evaluation to determine if 
there is merit to the claims. The Editors reserve the right to involve 
the Joint Journal Oversight Committee, Executive Officers of AMP 
or ASIP, and/or legal counsel as deemed appropriate. If the 
manuscript is currently under review, the review process will be put 
on hold pending resolution. If the claims appear to have merit, the 
next step is to contact the authors.  
The Editor-in-Chief will contact the corresponding author and 
request a formal written response to the Editors’ concerns, and may 
ask to see source data, within 30 days. Authors are expected to 
cooperate fully and in good faith. Upon review of said explanation 
and data, the Editors and Editorial Office will determine whether an 
innocent error was committed (requiring publication of a Correction 
or Retraction) or whether further reporting or investigation is 
warranted. If needed, the authors’ institutions and/or funding 
agencies will be contacted, as it is not the responsibility of the 
Journal to perform such an investigation. During the investigation, 
the Journal will not receive or review new manuscripts from authors 
named in the disputed manuscript.  
The appropriate authorities at the authors’ institutions and/or funding 
agencies will be notified of the original complaint and may be asked 
to conduct an independent investigation. Once an investigation has 
begun, the Editors may choose to publish a Note of Concern 
informing the scientific community that an investigation is underway 
regarding the article in question. The investigation is expected to 
proceed in a timely manner, and upon completion of an investigation, 
the institution should quickly notify the Journal of its findings.  
If an institution or funding agency declines to conduct an 
investigation on a timely basis, or if an author does not have such an 
affiliation, the Journal may conduct its own investigation. 
If all authors are cleared of any wrongdoing, an unpublished 
manuscript may re-enter the review process. If a Note of Concern 
was published, the Journal will publish a Correction to rectify the 
matter in the public record. 
Upon receiving final determination of misconduct (including final 
appeal), the Journal may publish a Correction, Note of Concern, or 
Retraction, depending on the findings of the investigation and the 
effect on the paper as a whole. If misconduct is determined by the 
authors’ institutions, then the Editors may request that the authors 
retract their paper. If the authors refuse, the Journal will notify all 
authors of the intent to publish a Retraction, to which the authors 
have 30 days to respond. The final Retraction will describe the reason 
for retraction as well as a list of authors agreeing (and if necessary 
those disagreeing) with the retraction. For unpublished manuscripts, 
the manuscript may be rejected or acceptance may be rescinded. 
Depending on the severity of the misconduct committed, the authors 
may be excluded from submitting new manuscripts for a period of 
time. 
At any point during the course of the investigation, the authors may 
withdrawal their unpublished manuscript or request a Retraction. If 
this occurs prior to formal investigation, the Editors may still 
determine to inform the authors’ institutions and/or funding agencies. 
These procedures do not supersede or diminish the general authority 
of the Journal to reject a manuscript as part of the review process. 
Procedures for Suspected Editorial Misconduct (Reviewers, Editors, 
Staff). Upon written notification of possible editorial misconduct, the 
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Editors and/or Editorial Office will first perform a preliminary 
evaluation to determine if there is merit to the claims. If the 
complaint involves an Editor or Journal staff, that person will be 
excluded from any review. The Editors reserve the right to involve 
the Joint Journal Oversight Committee, Executive Officers of ASIP 
or AMP, and/or legal counsel as deemed appropriate. If the claims 
appear to have merit, the next step is to contact the person involved.  
The Editor-in-Chief or Executive Officer of ASIP or AMP will 
contact the person involved, requesting a formal response to the 
concerns within 30 days. Upon review of said explanation, the 
Editors and Editorial Office will determine whether an innocent error 
was committed or whether further investigation or reporting is 
warranted. If needed, the person’s institution and/or funding agency 
will be contacted, as it is not the responsibility of the Journal to 
perform such an investigation. During the investigation, the Editor or 
Reviewer will be excluded from reviewing or submitting new 
manuscripts.  
The appropriate authorities at the person’s institution will be notified 
of the original complaint and may be asked to conduct an 
independent investigation. The investigation is expected to proceed in 
a timely manner, and upon completion of an investigation, the 
institution should quickly notify the Journal of its findings.  
Upon receiving final determination of misconduct (including final 
appeal), the Journal may publish a Note of Concern if the disposition 
of a manuscript(s) was affected.   
Depending on the severity of the misconduct committed, the Editor, 
Reviewer, or Journal staff may be relieved of all future Journal-
related duties.  
These procedures do not supersede or diminish the general authority 
of the Journal to dismiss an Editor, Reviewer, or Journal staff. 
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